Below is the latest news and stock prices of the 30 companies operating in the fledgling but burgeoning psychedelic bio-pharmaceutical drug sector from the beginning of 2021 to date. The 30 companies are divided into the 15 constituents in the munKNEE Pure-Play Psychedelic Drug Stocks Index, 3 larger cap companies and 12 other smaller cap companies. All prices are in USD unless otherwise noted. 6 marginal companies noted below are excluded from the analysis.

In addition, every company name has been hyperlinked to its corporate web site and every company trading symbol has been hyperlinked to in-depth financial data from TalkMarkets to provide the reader with further information to support whatever investment decisions they are contemplating.

The 15 munKNEE Pure-Play Psychedelic Drug Stocks Index constituents, in alphabetical order, are:

1. Champignon Brands (SHRMF) +6.5% to $0.66/share
   • announced the Company's appointment of Stephen R. Brooks as its new Chief Financial Officer and Peter Rizakos as the firm's new General Counsel.
2. Cybin (CLXPF) +30.0% to $1.95/share
   • provided an update on their patent filings and the development of their therapeutics program, which is expanding to include psychedelic compounds such as DMT, psilocybin analogues, and a range of tryptamines and phenylethylamines.
   • announce that it has entered into an agreement with neurotech pioneer HI, LLC dba Kernel to leverage its innovative technology, Kernel Flow, for its upcoming sponsored clinical work.
3. Havn Life (HAVLF) -11.7% to $0.68/share
   • partnered with Complex Biotech Discovery Ventures to begin Health Canada approved analysis of psilocybin under Havn Life’s section 56 exemption towards the development of a library of psilocybin compounds and lay the foundation for the future development of proprietary extraction methods.
4. Jaguar Health (JAGX) +307.4% to $3.30/share
   • announcement of its plan to develop and commercialize crofelemer, a new drug aimed at helping people with inflammatory diarrhea, including those who have recovered from COVID-19 but still experiencing symptoms, has caused its stock price to continue to climb (up 1900% since the end of October).
5. Mind Cure Health (MCURF) -5.3% to $0.54/share
   • announced the signing of a non-binding letter of intent for strategic investment and commercial cooperation with ATMA Journey Centers Inc. (the first commercial treatment center in Canada to announce providing psychedelic-assisted therapy for a section 56 exempt patient) empowering the Company with access to a global release strategy for iSTRYM, as well as international locations for translational research on novel molecules and treatment protocols.
6. Mydecine Innovations (MYCOF) +22.9% to $0.43/share
   • sponsored the first lab-based study of established microdosers led by Dr. Vince Polito at Macquarie University in Australia.
   • filed seven provisional patent applications with the United States Patent and Trademark Office in its efforts to discover valuable novel compounds in fungi for medicinal and pharmaceutical use.
7. Newscope Capital  (CSE: PHRM) (OTCQB: PHRRF) +25.0% to C$0.40/share
   • announced through its wholly-owned subsidiary, PharmaTher Inc., that its common shares have been approved for trading on the OTCQB as of this past Monday.
8. Novamind (NM) +6.4% to C$1.44/share
   • announced the expansion and optimization of its largest clinic, Cedar Psychiatry, in Layton, Utah.
9. Numinus Wellness (LKYSF) +25.0% to $1.05/share
   • signed a lab services agreement with Optimi Health Corp.(Private) to further the research and development of psilocybin-producing mushrooms.
10. Psyched Wellness (DCNPF) +4.5% to $0.23/share
    • commenced a study to determine the therapeutic values of muscimol for antioxidant and anti-inflammatory purposes.
11. Red Light Holland (TRUFF) N/C @ $0.22/share 
    • announced it has refiled its interim financial statements for the three and six month period ended September 30, 2020 as they have been restated to reflect certain adjustments resulting from a review by the Company's auditors.
12. Revive Therapeutics (RVVTF) +2.1% to $0.49/share
    • entered into a sponsored research agreement and an exclusive option to license agreement with North Carolina State University to develop a novel biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform.
13. Seelos Therapeutics (SEEL) +1.9% to $1.61/share
    • announced dosing of the first patients in its registrational Proof of Concept study of SLS-002 (intranasal racemic ketamine) for acute suicidal ideation and behavior in patients with major depressive disorder.
14. Silo Pharma (SILO) -16.7% to $0.35/share
    • announced that it has entered into a  sponsored research agreement with the University of Maryland, Baltimore relating to a study to examine a novel peptide-guided drug delivery approach for the treatment of multiple sclerosis.
15. Tryp Therapeutics (TRYP) -14.7% to C$0.64/share
    • appointed Dr. William K. Schmidt, a noted authority in the development of pain drugs, to its Scientific Advisory Board.

All in all, the above 15 stocks in the munKNEE Pure-Play Psychedelic Drug Stocks Index have appreciated 30.7% since the end of 2020. That being said, if Jaguar's out-sized increase of +307.4% was excluded from the comparison then the Index "only" appreciated by 8.07% during that 2-week period.

Larger Capitalized Psychedelic Drug Stocks

1. Compass Pathways (CMPS) -10.8% to $42.50/share
   • established its first Centre of Excellence in collaboration with The Sheppard Pratt Institute in Baltimore, Maryland, to accelerate research and improve patient experience in mental health care.
2. Field Trip Health (FTRPF) -5.8% to $3.06/share
   • closed their bought deal financing for gross proceeds of C$20M at a unit price of C$4.50, and announced they have been selected as a trial location for a MAPS-sponsored study on the safety, feasibility, and preliminary outcomes of MDMA-assisted therapy to treat eating disorders, including Anorexia Nervosa.
3. Mind Medicine (MMEDF) +1.3% to $3.09/share
   • announced an innovative randomized placebo-controlled study evaluating the effects of daytime and evening administration of low doses of LSD on cognitive performance, sleep quality, mood, neuroplasticity markers, emotion regulation, quality of life, and immune system response.

Nano-Cap Psychedelic Drug Stocks

1. Aion Therapeutic (AION) N/C @ C$0.12/share
   • no news
2. Better Plant Sciences (VEGGF) -15.4% to $0.11/share
   • no news
3. Core One Labs (CLABF) +21.4% to $0.85/share
   • announced plans to initiate another intellectual property strategy that will utilize its patented transmucosal thinstrip delivery method in combination with its proprietary biosynthetic psilocybin, developed by its wholly-owned subsidiary, Vocan Biotechnologies Inc.
4. Ehave (EHVVF) N/C @ $0.12/share
   • formed a partnership with Cognitive Apps to introduce revolutionary AI Voice Assistant that will revolutionize mental health in the psychedelic sector.
5. Entheon Biomedical (ENTBF) -9.6% to $0.66/share
   •  completed its acquisition of HaluGen Life Sciences Inc., a biotech company in the business of developing and commercializing a pre-screening test to identify genetic markers predictive of an individual's reaction to hallucinogenic drugs.
6. Lobe Sciences (GTSIF) N/C @$0.10/share
   • announced a further upsize to its non-brokered private placement from C$2.7M to C$3.4M, and has completed a second and final tranche closing for gross proceeds of C$1.1M.
7. M2Bio Sciences (WUHN) N/A $0.39/share
   • announced the acquisition of Tsime Pharmaceuticals (Pty) Ltd which will become a subsidiary of MJ Medtech Inc.
8. Mindset Pharma (MSET) N/A C$0.85/share
   • announced that certain compounds belonging to its third family of patent-pending next generation psychedelic compounds are exhibiting positive in vitro characteristics.
9. NeonMind Biosciences (NEON) N/A C$0.24/share
   • filed 5 U.S. provisional patent applications which include the administration of psychedelic compounds to aid in weight loss, treat obesity and its complications, reduce food cravings, treat compulsive eating disorder, and assist in altering the diet of an individual.
   • acquired ~18% of Translational Life Sciences, a start-up biotechnology company with experience in designing and conducting clinical trials.
10. New Wave Holdings (TRMNF) +37.5% to $0.11/share
    • entered into a share exchange agreement with the Company, Way of Will Inc. and its shareholders pursuant to which, the Company will acquire 100% of the issued and outstanding securities of WoW
11. Nova Mentis Life Science (LIBFF) +11.8% to $0.19/share
    • appointed Dr. Kyle H. Amber, Ph.D., currently the Director of Data Science at Nike, to its Scientific Advisory Board.
12. Pure Extracts Technologies (PRXTF) +7.8% to $0.55/share
    • increased its non-brokered private placement offering to C$5M, and closed a lead order for gross proceeds of C$3M.

The above 12 psychedelic stocks went up 10.6%, on average, during the first two weeks of 2021.

Legend: Nano-Cap: Market Cap of $50M or less; N/C: No Change; N/A: (Not Applicable as not listed at end of 2020.)

For the record, 6 marginal psychedelic drug stocks are excluded from the above analysis as they are thinly traded and/or do not devote 100% of their efforts to the research and development of drugs based on psychedelic components. The 6 companies are: Graph Blockchain (REGRF), Minerco (MINE), Thoughtful Brands (PEMTF), Nutritional High (SPLIF), Codebase (BKLLF) and Hollister (HSTRF).